Sanofi Consumer Healthcare India DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Dec 2025FY25Dec 2024
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.74×0.75×0.73×
1.05×1.08×0.93×
36.4%33.8%36.7%
1.80×1.80×1.68×
1.42×1.42×1.58×
73.3%70.1%66.3%
73.1%73.1%66.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

SANOFICONR₹3,468.00

Sanofi Consumer Healthcare India Limited

· Pharma & Health
₹ CrorePeersPGHLSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹7,976 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/12/2024
FY26
31/12/2025
Last 12M
30/09/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.730.750.74
Interest Burden (Pretax/EBIT) ×0.931.081.05
EBIT Margin %36.7333.8536.42
Asset Turnover ×1.681.801.80
Financial Leverage (Assets/Equity) ×1.581.421.42
ROE (5-step product, year-end total equity) %66.3170.0973.26
ROE (owners' profit / average owners' equity) %66.3073.0973.09
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.